We preview the potential major trial milestones, presentations and FDA calendar for the biotech sector in the week ahead
A synopsis of recent analyst activity that could buoy these small cap biotech stocks in trading today
Portola received FDA Approval for Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors
